|Bid||30.16 x 1100|
|Ask||31.03 x 800|
|Day's Range||29.82 - 30.65|
|52 Week Range||14.86 - 34.80|
|Beta (5Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Nov 10, 2010|
|1y Target Est||35.06|
3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced statistically significant topline data from the first Phase 3 trial (GOBI trial) evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD).
Many are still up for grabs, as investors would rather pay a high price for companies that are steadily growing their cash flows than pay for ones having temporary problems with theirs. Today, let's look at why brave investors can benefit from going long on shares of AMC Entertainment Holdings (NYSE: AMC), Bausch Health (NYSE: BHC), and Aurora Cannabis (NYSE: ACB). Theater chain AMC Entertainment Holdings has had a rough time after it had to cease operations for months because of COVID-19-related restrictions.